Shu‐Ling Fu

1.5k total citations
57 papers, 1.3k citations indexed

About

Shu‐Ling Fu is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Shu‐Ling Fu has authored 57 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 19 papers in Immunology and 12 papers in Oncology. Recurrent topics in Shu‐Ling Fu's work include Andrographolide Research and Applications (11 papers), Immune Response and Inflammation (9 papers) and PARP inhibition in cancer therapy (6 papers). Shu‐Ling Fu is often cited by papers focused on Andrographolide Research and Applications (11 papers), Immune Response and Inflammation (9 papers) and PARP inhibition in cancer therapy (6 papers). Shu‐Ling Fu collaborates with scholars based in Taiwan, United States and Canada. Shu‐Ling Fu's co-authors include Chao‐Hsiung Lin, Shih‐Kai Hung, Peter K. Vogt, Jih‐Jung Chen, Ling-Chien Hung, Cheng‐Deng Kuo, Wey‐Jinq Lin, Ming‐Jen Cheng, Yi‐Ying Chiou and Jen‐Hwey Chiu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and PLoS ONE.

In The Last Decade

Shu‐Ling Fu

57 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shu‐Ling Fu Taiwan 22 623 258 230 218 146 57 1.3k
Dongmei Wang China 21 808 1.3× 380 1.5× 266 1.2× 296 1.4× 187 1.3× 63 1.7k
Steven J. Melnick United States 20 626 1.0× 230 0.9× 145 0.6× 142 0.7× 122 0.8× 52 1.6k
Rahul Checker India 22 789 1.3× 157 0.6× 161 0.7× 87 0.4× 111 0.8× 55 1.4k
Linzhong Yu China 18 559 0.9× 153 0.6× 222 1.0× 81 0.4× 95 0.7× 52 1.1k
Chunliu Mi China 22 689 1.1× 148 0.6× 110 0.5× 157 0.7× 122 0.8× 41 1.1k
Ting Fan China 15 539 0.9× 108 0.4× 314 1.4× 202 0.9× 164 1.1× 28 1.2k
Damodar Gupta India 17 608 1.0× 183 0.7× 294 1.3× 188 0.9× 62 0.4× 34 1.7k
Dorrah Deeb United States 24 1.3k 2.1× 143 0.6× 177 0.8× 129 0.6× 124 0.8× 45 1.8k
Weidong Zhang China 25 1.2k 1.9× 203 0.8× 181 0.8× 286 1.3× 170 1.2× 86 2.0k
Manzar Alam India 22 597 1.0× 142 0.6× 85 0.4× 225 1.0× 126 0.9× 38 1.4k

Countries citing papers authored by Shu‐Ling Fu

Since Specialization
Citations

This map shows the geographic impact of Shu‐Ling Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Ling Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Ling Fu more than expected).

Fields of papers citing papers by Shu‐Ling Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Ling Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Ling Fu. The network helps show where Shu‐Ling Fu may publish in the future.

Co-authorship network of co-authors of Shu‐Ling Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Ling Fu. A scholar is included among the top collaborators of Shu‐Ling Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Ling Fu. Shu‐Ling Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Chian‐Feng, Shin-E Wang, Shih‐Chin Chen, et al.. (2024). Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382. Phytomedicine. 132. 155860–155860. 3 indexed citations
2.
Lin, Chao‐Hsiung, et al.. (2023). Hypericum sampsonii exhibits anti-inflammatory activity in a lipopolysaccharide-induced sepsis mouse model. Journal of Traditional and Complementary Medicine. 13(4). 379–388. 3 indexed citations
3.
Chiang, Teresa Po‐Yu, et al.. (2023). Design, synthesis, and anti-cancer evaluation of C-14 arylcarbamate derivatives of andrographolide. Bioorganic & Medicinal Chemistry. 98. 117582–117582. 2 indexed citations
4.
Fu, Shu‐Ling, et al.. (2023). Galgravin Isolated from Piper kadsura Ameliorates Lipopolysaccharide (LPS)-Induced Endotoxemia in Mice. International Journal of Molecular Sciences. 24(23). 16572–16572. 2 indexed citations
5.
Wu, Chien‐Tung, et al.. (2023). Traditional herbal medicine and the decreased risk of uterine surgery among women with uterine fibroid in Taiwan. Journal of Herbal Medicine. 42. 100759–100759. 3 indexed citations
6.
Ping, Yueh‐Hsin, Hsin Yeh, Li-Wei Chu, et al.. (2022). The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research. Frontiers in Pharmacology. 13. 744439–744439. 15 indexed citations
7.
Cheng, Ming‐Jen, et al.. (2021). Rare Chromone Derivatives from the Marine-Derived Penicillium citrinum with Anti-Cancer and Anti-Inflammatory Activities. Marine Drugs. 19(1). 25–25. 23 indexed citations
8.
Yang, Jen‐Hao, et al.. (2021). Arginine Methylation of hnRNPK Inhibits the DDX3-hnRNPK Interaction to Play an Anti-Apoptosis Role in Osteosarcoma Cells. International Journal of Molecular Sciences. 22(18). 9764–9764. 11 indexed citations
9.
10.
Chou, Yi-Ju, Yi‐Long Huang, Chung‐Ming Sun, et al.. (2019). Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein. Biochemical Pharmacology. 163. 308–320. 29 indexed citations
11.
Fu, Shu‐Ling, et al.. (2018). Andrographolide enhances the anti-metastatic effect of radiation in Ras-transformed cells via suppression of ERK–mediated MMP-2 activity. PLoS ONE. 13(10). e0205666–e0205666. 19 indexed citations
12.
Chiu, Yung‐Tsung, et al.. (2015). Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation. Journal of Biomedical Science. 22(1). 63–63. 45 indexed citations
13.
Chang, Yu‐Ling, Ping‐Hui Tseng, Shie‐Liang Hsieh, et al.. (2014). A novel TLR2‐triggered signalling crosstalk synergistically intensifies TNF‐mediated IL‐6 induction. Journal of Cellular and Molecular Medicine. 18(7). 1344–1357. 14 indexed citations
14.
Su, Yu‐Chieh, Fei‐Ting Hsu, Shu‐Ling Fu, et al.. (2014). Everolimus sensitizes Ras-transformed cells to radiation in vitro through the autophagy pathway. International Journal of Molecular Medicine. 34(5). 1417–1422. 10 indexed citations
15.
Lin, Chao‐Hsiung, Pei‐Fen Chen, Cheng‐Deng Kuo, et al.. (2013). Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochemical Pharmacology. 87(2). 229–242. 34 indexed citations
16.
Lin, Chao‐Hsiung, Tung Chao, Cheng‐Deng Kuo, et al.. (2013). The suppression of thoc1 in cancer cell apoptosis mediated by activated macrophages is nitric oxide-dependent. Biochemical Pharmacology. 86(2). 242–252. 14 indexed citations
17.
Fu, Shu‐Ling, et al.. (2012). A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1834(2). 508–515. 32 indexed citations
18.
Fu, Shu‐Ling, et al.. (2011). Aurora-A phosphorylates hnRNPK and disrupts its interaction with p53. FEBS Letters. 585(17). 2671–2675. 23 indexed citations
19.
Hung, Shih‐Kai, et al.. (2011). Immunosuppressive Effects of Fisetin in Ovalbumin-Induced Asthma through Inhibition of NF-κB Activity. Journal of Agricultural and Food Chemistry. 59(19). 10496–10504. 49 indexed citations
20.
Fu, Shu‐Ling, et al.. (2005). Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: A new cell model for studying carcinogenesis. Biochemical and Biophysical Research Communications. 338(2). 830–838. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026